Fiona Dunbar
Oxford, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine) in patients with treatment-resistant depression.
Journal: Journal of psychopharmacology (Oxford, England)
Published: February 27, 2026
Psychological change processes in alcohol use disorder: A qualitative study of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) with cognitive behavioural therapy.
Journal: Addiction (Abingdon, England)
Published: October 19, 2025
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trial.
Journal: Addiction (Abingdon, England)
Published: June 11, 2025
Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults.
Journal: Scientific reports
Published: October 23, 2024
Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants.
Journal: Journal of psychopharmacology (Oxford, England)
Published: April 15, 2024
Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study.
Journal: Headache
Published: November 13, 2023
A narrative synthesis of research with 5-MeO-DMT.
Journal: Journal of psychopharmacology (Oxford, England)
Published: October 20, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026